Defining the correlates of lymphopenia and independent predictors of poor clinical outcome in adults hospitalized with COVID-19 in Australia
Open Access
- 15 May 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Abstract
Lymphopenia is a common feature of acute COVID-19 and is associated with increased disease severity and 30-day mortality. Here we aim to define the demographic and clinical characteristics that correlate with lymphopenia in COVID-19 and determine if lymphopenia is an independent predictor of poor clinical outcome. We analysed the ENTER-COVID (Epidemiology of hospitalized in-patient admissions following planned introduction of Epidemic SARS-CoV-2 to highly vaccinated COVID-19 naïve population) dataset of adults (N = 811) admitted for COVID-19 treatment in South Australia in a retrospective registry study, categorizing them as (a) lymphopenic (lymphocyte count < 1 × 109/L) or (b) non-lymphopenic at hospital admission. Comorbidities and laboratory parameters were compared between groups. Multiple regression analysis was performed using a linear or logistic model. Intensive care unit (ICU) patients and non-survivors exhibited lower median lymphocyte counts than non-ICU patients and survivors respectively. Univariate analysis revealed that low lymphocyte counts associated with hypertension and correlated with haemoglobin, platelet count and negatively correlated with urea, creatinine, bilirubin, and aspartate aminotransferase (AST). Multivariate analysis identified age, male, haemoglobin, platelet count, diabetes, creatinine, bilirubin, alanine transaminase, c-reactive protein (CRP) and lactate dehydrogenase (LDH) as independent predictors of poor clinical outcome in COVID-19, while lymphopenia did not emerge as a significant predictor.Keywords
This publication has 30 references indexed in Scilit:
- Mortality trends and length of stays among hospitalized patients with COVID-19 in Ontario and Québec (Canada): a population-based cohort study of the first three epidemic wavesInternational Journal of Infectious Diseases, 2022
- Association of lymphocyte subsets with mortality in severe COVID‐19 pneumonia patientsJournal of Clinical Laboratory Analysis, 2021
- SARS-CoV-2, COVID-19 and the aging immune systemNature Aging, 2021
- Lymphopenia in Covid-19: A single center retrospective study of 589 casesAnnals of Medicine & Surgery, 2021
- Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitusJournal of Diabetes and its Complications, 2021
- Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19)JAMA Network Open, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive studySignal Transduction and Targeted Therapy, 2020
- Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortalityJournal of Infection, 2019
- Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of MortalityEBioMedicine, 2017